Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.250 EUR
−187.58 M EUR
461.47 M EUR
97.00 M
About NovoCure Limited
Sector
Industry
CEO
Asaf Danziger
Website
Headquarters
St. Helier
Founded
2000
ISIN
JE00BYSS4X48
FIGI
BBG00B5YGRM4
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange NOVOCURE LTD stocks are traded under the ticker 038.
We've gathered analysts' opinions on NOVOCURE LTD future price: according to them, 038 price has a max estimate of 36.84 EUR and a min estimate of 16.58 EUR. Watch 038 chart and read a more detailed NOVOCURE LTD stock forecast: see what analysts think of NOVOCURE LTD and suggest that you do with its stocks.
Yes, you can track NOVOCURE LTD financials in yearly and quarterly reports right on TradingView.
NOVOCURE LTD is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
038 earnings for the last quarter are −0.25 EUR per share, whereas the estimation was −0.30 EUR resulting in a 16.12% surprise. The estimated earnings for the next quarter are −0.34 EUR per share. See more details about NOVOCURE LTD earnings.
NOVOCURE LTD revenue for the last quarter amounts to 139.30 M EUR, despite the estimated figure of 129.29 M EUR. In the next quarter, revenue is expected to reach 145.35 M EUR.
038 net income for the last quarter is −27.46 M EUR, while the quarter before that showed −31.16 M EUR of net income which accounts for 11.88% change. Track more NOVOCURE LTD financial stats to get the full picture.
No, 038 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 16, 2024, the company has 1.45 K employees. See our rating of the largest employees — is NOVOCURE LTD on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVOCURE LTD EBITDA is −125.14 M EUR, and current EBITDA margin is −42.25%. See more stats in NOVOCURE LTD financial statements.
Like other stocks, 038 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVOCURE LTD stock right from TradingView charts — choose your broker and connect to your account.